Astrazeneca (AZN) Gains from Investment Securities (2009 - 2026)

Astrazeneca's Gains from Investment Securities history runs 17 years deep, the most recent figure standing at -$526.0 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 44.9% year-over-year to -$526.0 million; the TTM figure through Mar 2026 stood at -$176.0 million (down 379.37% YoY), while the FY2025 annual figure was -$13.0 million, down 225.0% from the prior year.
• Gains from Investment Securities was -$526.0 million for Q1 2026 at Astrazeneca, down from $2.2 billion in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $2.2 billion in Q4 2025 to a low of -$1.2 billion in Q2 2025.
• Historically, Gains from Investment Securities has averaged -$96.4 million across 5 years, with a median of -$526.0 million in 2026.
• Biggest YoY gain for Gains from Investment Securities was 795.37% in 2022; the steepest drop was 2433.33% in 2022.
• A 5-year view of Gains from Investment Securities shows it stood at $1.8 billion in 2022, then tumbled by 146.42% to -$836.0 million in 2023, then soared by 336.12% to $2.0 billion in 2024, then grew by 10.44% to $2.2 billion in 2025, then slumped by 124.13% to -$526.0 million in 2026.
• The last three Gains from Investment Securities figures came in at -$526.0 million (Q1 2026), $2.2 billion (Q4 2025), and -$644.0 million (Q3 2025), per Business Quant data.